Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-02-04
Target enrollment:
Participant gender:
Summary
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with
apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a
high risk of recurrence
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital